Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis - 06/05/20

Doi : 10.1016/j.retram.2020.04.001

H. Wiebach ^a , D. Gezer ^a , T.H. Brummendorf ^a , M. Crysandt ^a,^{^{1
These authors distributed equally to this work},}⁎ , S. Wilop ^a,^b,^{^{1
These authors distributed equally to this work}}
^a Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
^b MVZ West GmbH Wuerselen, Hematology - Oncology, Wuerselen, Germany

^⁎Corresponding author at: Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany.Department of Hematology, Oncology, Hemostaseology, and Stem Cell TransplantationMedical FacultyRWTH Aachen UniversityPauwelsstr. 30Aachen52074Germany

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Wednesday 06 May 2020
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Purpose of the study

In the past years, high dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)has more extensively been performed in elderly patients with multiple myeloma (MM). Several studies found a similar survival benefit compared to younger patients. The objective of our retrospective study is to analyse the tolerability of HDT + ASCT in elderly patients.

Patients and methods

We compared 26 ASCT performed in MM patients ≥65 years to 127 ASCT in patients <65 years by evaluating treatment-tolerability, length of hospital stay and number of transfusions.

Results

There was no significant difference in the duration of hospitalisation (16 days (range 14–47) in the elderly vs. 17 days (range 14–71) days, P = 0.0903), median time of cytopenia (neutrophils<500/μl: 5 days (range 4–24) vs. 6 days (range 3–28) days, P = 0.1091; platelets<30 000/μl: 6 days (range 3–36) vs. 7 days (range 0–53) days, P = 0.274) or incidence of, or degree of complications between the two age-groups. Immediate and day 100 treatment related mortality (TRM) was comparable in both groups (3.85% vs. 1.58%, P = 0.4304).